anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: To estimate the prevalence and dynamics of human papillomavirus (HPV) infection, over a 5-year period, among Saudi women.
METHODS: A 2-phase, population-based study combining cross-sectional and cohort designs was carried out with 5360 ever-married women aged 30-65 from Jeddah, Saudi Arabia, between 2013 and 2018. Participants were enrolled in a designated screening program and screened using the hybrid capture 2 HPV test. Women testing positive for HPV were followed up after one year to estimate the HPV clearance rate, while those testing negative had a follow-up after 5 years to assess new HPV infections. Factors associated with HPV positivity and clearance, including sociodemographic and clinical aspects, were analyzed.
RESULTS: Participant's mean age was 44.3 and the average marriage duration was 22.6 years. The initial HPV prevalence was 4.7%. After one year, the HPV clearance rate among initially positive women was 84.3%. The rate of new HPV infections among initially negative women after 5 years was 0.2%, resulting in a cumulative HPV prevalence of 5% over the study period. The incidence rate was estimated at 47 per 100,000 person-years. Parity was the only independent factor inversely associated with HPV positivity, with an odds ratio of 0.93 (95% confidence interval: 0.8 - 0.99).
CONCLUSION: The prevalence of HPV in Saudi women was relatively low, suggesting a low transmission rate of HPV. This finding indicates the need for continuous monitoring and tailored prevention strategies.
Miscarriage is basically defined as intrauterine fetal death before viability (1,2). Age of viability, in Egypt, sets at 26 weeks of gestation (3). Incidence of miscarriage is often referred to as an iceberg where the actual size of the problem cannot be determined. More than 50% of human conceptions are lost before the missed period either before or after implantation (4). In clinically recognized pregnancies, losses decrease as pregnancy progresses from 17% - 20 % after 6 weeks to only 3% at 10 weeks gestation (4). Beside the high incidence of miscarriage, it implies a high psychological morbidity to both partners with increased liability to anxiety, post stress disorder and depression(5,6). This psychological impact can be attributed not only to loss of desired child but also to the traumatic event of bleeding and pain encountered by those patients (7).

While the clinical management of miscarriage and its physical complications have been extensively discussed; the psychological impact of this traumatic event of loss is usually overlooked especially in developing countries (8-11). Moreover, there are behind-the-scene factors that trigger or correlate to the development of psychiatric morbidities following miscarriage (12,13). Factors as sociodemographic, marital satisfaction, social support, individual's coping resources, history of infertility and previous miscarriage vary across different population samples, also vary in their influence on women's psychological resilience after traumatic events as miscarriage. No previous studies addressed this topic in Egyptian population.
NEW MATERIAL:An amide derivative obtained by subjecting a sulfur-containing amine and 5-18C unsaturated fatty acid amide to amide bond formation. USE:An antiulcer and an anti-inflammatory drug. PREPARATION:For example, an unsaturated fatty acid or its reactive derivative is reacted with a sulfur-containing amine optionally in the presence of a dehydrating agent, to give the aimed substance. A compound shown by the formula I (m+n=1-14) such as 2-octenoic acid, 2-decenoic acid, 2-undecenoic acid, etc., is preferable as the unsaturated fatty acid. A compound shown by the formula II (p+q is 1-14; A is alkylene; X is H, carbamoylalkyl or group shown by the formula III) is cited as a preferable mode of the amide derivative. For example, N,N'-dicyclohexylcarbodiimide, etc., is used as the dehydrating agent.
This was a randomized, open-label, multi-center study of the safety, overall tolerability, and antiviral activity of BCV, as compared with SoC, in pediatric (and young adults in the United States) recipients of high-risk (i.e., T cell-depleted and/or unrelated cord blood graft, or a T cell-replete graft from ahaploidentical donor with post-transplant cyclophosphamide administration) allogeneic HCT. Subjects with AdV detected in plasma after their qualifying transplant could be screened for participation in the study. Subjects who met all applicable entry criteria were randomized in a 2:1 ratio to receive either BCV or SoC (i.e., investigator-assigned therapy). The formulation of BCV used in this study was oral tablet/suspension. Subjects were randomized within 100 days post-transplant; for study purposes, the day of randomization was defined as Day 1. During randomization, subjects were stratified based on the following variables: last AdV viremia (≥10,000 copies/mL versus \<10,000 copies/mL) measurement available from the designated central virology laboratory prior to randomization, time from transplant to randomization (≥28 days versus \<28 days), and T cell-depletion methodology (receipt of alemtuzumab or ex vivo depletion versus receipt of anti-thymocyte globulin \[ATG\] or no T cell depletion).
Drugs now used in treatment for patients with AIDS show some toxicity which limits their usefulness. In addition, with long-term treatment with AZT, there is evidence of virus resistance to the drug. Compounds that are more effective and less toxic than those in present use would be beneficial, especially if they are active against AZT-resistant viruses. Nevirapine has shown in vitro (test tube studies) activity in inhibiting HIV replication (reproduction). In vitro studies have shown that nevirapine and AZT work together to inhibit HIV replication.

Groups of 10 patients are studied at each of three dose levels. Five patients at each dose level have less than 3 months of prior AZT treatment; five patients at each dose level have at least 12 months of previous AZT treatment and tolerated an AZT regimen of 600 mg/day (200 mg every 8 hours). At least 24 patient-weeks of treatment with the combination treatment must be completed without requiring dose interruption before the next dosage level can be started. All 30 patients must be enrolled at a lower dosage level before a higher dosage level is started. Patients begin treatment with AZT. 14 days later, patients begin treatment with nevirapine in addition to the AZT. After 24 weeks, patients have the option to continue long-term treatment with either nevirapine or standard treatment.
FIELD: medicine; pharmaceuticals.SUBSTANCE: invention relates to medicine and pharmaceutics, in particular to an article for treating and creating experimental models of gastrointestinal disorders, due to the therapeutic action of living probiotic bacteria cultivated in situ in a bioengineering structure. Disclosed is a bioengineering structure for probiotic bacteria of genera Lactobacillus and Bifidobacterium, which is a layer of porous microspheres in a hydrogel arranged on a porous substrate. Porous substrate is made from poly-3-oxybutyrate and/or its copolymer with 3-oxyvalerate with molecular weight from 1 × 105to 2 × 106g/mol and is characterized by the presence of through pores (or bonded pores), total porosity from 75 to 99 %, average pore diameter from 0.5 to 20 mcm. Porous microspheres are made from poly-3-oxybutyrate with molecular weight from 1 × 104to 1 × 106g/mol and are characterized by availability of through pores (or connected pores), total porosity from 75 to 99 %, average pore diameter from 0.5 to 20 mcm. Pores of substrate and microspheres are filled with hydrogel containing probiotic bacteria. Hydrogel is made from bacterial alginate with molecular weight from 105to 106g/mol, molar content of guluronic acid residues in polymer from 31 mol. % to 48 mol. % and acetylation level is from 10 mol. % to 46 mol. %. Besides, a method of producing the above bioengineered structure is proposed.EFFECT: technical result is obtaining a hybrid bioengineering structure based on probiotic bacteria and bacterial polymers (poly-3-oxyalkanoate and alginate), providing at least 95 % survival rate of bacteria, as well as increasing their protection (increase in bacteria survival by at least 50 %) in an unfavorable medium while preserving biocompatibility (no cytotoxicity) of the construct in vitro.18 cl, 2 dwg, 4 ex
This 3 weeks study examines the correlation between stress and alcohol using an ecological, prospective design. Participants will be given phone calls 4 times a day for 3 weeks, assessing perceived stress and alcohol related craving.
Less frequently reported adverse reactions are vaginal bleeding, vaginal discharge, menstrual irregularities, skin rash and headaches. Usually these have not been of sufficient severity to require dosage reduction or discontinuation of treatment. Very rare reports of erythema multiforme, Stevens-Johnson syndrome, bullous pemphigoid, interstitial pneumonitis, and rare reports of hypersensitivity reactions including angioedema have been reported with tamoxifen therapy. In some of these cases, the time to onset was more than one year. Rarely, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen (see PRECAUTIONS, Drug/Laboratory Testing Interactions).

To report SUSPECTED ADVERSE EVENTS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088or http://www.fda.gov/ for voluntary reporting of adverse reactions.
Once consented, each participant underwent a video fluoroscopic swallow study (VFSS). Each participant was fed room temperature thin liquid barium (Varibar® Thin Liquid Barium Sulfate for Suspension) from a standard bottle (60ml Similac® Volu-Feeder®) with an attached Similac® Infant Nipple and Ring. The swallows were assessed in real time for any swallowing dysfunction and saved electronically. These swallows were labeled "RTS" for "room temperature swallows. If no swallow dysfunction was observed, the participant became ineligible and the study ended. If swallow dysfunction was observed, the participant became eligible to complete the other arms of the study.
The invention discloses a kind of bronchitis piece Film coated tablets and preparation method thereof, the bronchitis piece Film coated tablets refers to that coating water-soluble thin film coating material by mist on the surface of bronchitis piece plain piece is formed by bronchitis tablet；The method for preparing bronchitis piece Film coated tablets includes preparing the technical process such as film coating liquid, film coating；Bronchitis piece Film coated tablets prepared by the present invention has the advantage that compared with bronchitis piece in the prior art and 1. uses auxiliary material few, reduce production cost；2. it is broken to reduce tablet, yield is improved, the production time is substantially reduced, is conducive to environmental protection；3. improving the mode of appearance of tablet, humidity resistance is good, increases the stability of drug；4. increasing the dissolution rate of tablet, it is disintegrated drug rapidly, it is rapid-action；5. manufactured drug expands target user, especially suitable diabetic is taken；6. being conducive to quality by improving quality standard and controlling.
Selective serotonin reuptake inhibitors (SSRIs) became the first line therapy for anxiety and depressive disorders and for many other clinical diagnoses. One of the most disturbing side effects that is observed is a tendency towards aggressiveness among patients receiving medications from this group, mainly during the first (one month) period of therapy. Aggressive behavior tends to occur in some individuals but not in others. Until now most of the cases and reports in the literature demonstrate the extreme events of aggressive behavior. These personality or any other character traits that are more prone to develop aggressiveness have not been studied and it is not clear if this side effect manifests itself just in the extreme rare cases or if it is a more common phenomenon that occurs in a wider group of people.

In this study we try to estimate the tendency towards aggressive behavior of patients prescribed to a medication of the SSRI group. By using a comparative computer simulation we hope to be able to detect more delicate changes and maybe to get some clues of the personalities prone to aggressive behavior in the future.
Alzheimer's disease (AD) is a multifaceted neurodegenerative disorder for which the underlying causes remain largely unknown. Therefore, the development of imaging agents capable of detecting biomarkers associated with this disease is crucial. Dual-functional probes are particularly important as they can track two biomarkers at the same time and examine their interaction. Herein, Two red-emissive dual-functional fluorescent probes, RC-1 and RA-2, have been designed and synthesized based on the Rofecoxib scaffold. When probes (RC-1 and RA-2) are in viscous media or bound to Aβ aggregates, there is a dramatic enhancement in fluorescence emission due to the constraint of the twisted intramolecular charge transfer effect (TICT). RC-1 with ideal blood-brain barrier (BBB) penetrability enables visualization of Aβ plaques in vivo AD mice. These results suggest that RC-1 and RA-2 have the potential to serve as powerful fluorescence imaging agents for Aβ and mitochondria-related pathology in AD.
BACKGROUND: Most previous studies of rheumatoid arthritis (RA) and cancer risk have lacked information on potential confounding factors. We investigated RA-associated cancer risks in a large cohort of women in the UK, taking account of shared risk factors.
METHODS: In 1996-2001, women aged 50-64, who were invited for routine breast screening at 66 National Health Service (NHS) screening centres in England and Scotland, were also invited to take part in the Million Women Study. Participants provided information on sociodemographic, lifestyle and health-related factors, including RA, and were followed up for cancers and deaths. Cox regression yielded RA-associated hazard ratios (HRs) of 20 cancers, adjusted for 10 characteristics including smoking status and adiposity.
RESULTS: Around 1.3 million women (half of those invited) were recruited into the study. In minimally adjusted analyses, RA was associated with the risk of 13 of the 20 cancers. After additional adjustment for lifestyle factors, many of these associations were attenuated but there remained robust evidence of RA-associated increases in the risk of lung (HR 1.21, 95% confidence interval 1.15-1.26), lymphoid (1.25, 1.18-1.33), myeloid (1.12, 1.01-1.25), cervical (1.39, 1.11-1.75) and oropharyngeal (1.40, 1.21-1.61) cancers, and decreases in the risk of endometrial (0.84, 0.77-0.91) and colorectal (0.82, 0.77-0.87) cancers.
CONCLUSIONS: After taking account of shared risk factors, RA is positively associated with lung and certain blood and infection-related cancers, and inversely associated with colorectal cancer. These findings are consistent with existing hypotheses around immune response, susceptibility to infections, and chronic inflammation. The inverse association observed for endometrial cancer merits further investigation.
The study had two groups of participants: the LED group (GL) and the control group (GC), both with Membracel®, a porous membrane that regenerates crystalline cellulose, as the primary cover in the donor area of the skin graft (no secondary cover was used) ). In one of the groups (GL), a light-emitting diode (LED) plate was applied, which was covered with sterile waterproof and transparent film to prevent contamination. The participant was positioned so that the skin graft donor area was accessible. The LED plate covered the entire skin donor area and was irradiated with a radiant exposure of 1.53J / cm2 and irradiance of 2.55 mW / cm2 for 10 minutes. The LED plate was applied in contact with the skin graft donor area in the immediate postoperative period and on Membracel® on the 1st, 3rd, 5th and 7th postoperative days. The primary coverage remained until spontaneous removal.
Immunoglobulin G (IgG) is the main isotype of antibody in human blood. IgG consists of four subclasses (IgG1 to IgG4), encoded by separate constant region genes within the Ig heavy chain locus (IGH). Here, we report a genome-wide association study on blood IgG subclass levels. Across 4334 adults and 4571 individuals under 18 years, we discover ten new and identify four known variants at five loci influencing IgG subclass levels. These variants also affect the risk of asthma, autoimmune diseases, and blood traits. Seven variants map to the IGH locus, three to the Fcγ receptor (FCGR) locus, and two to the human leukocyte antigen (HLA) region, affecting the levels of all IgG subclasses. The most significant associations are observed between the G1m (f), G2m(n) and G3m(b*) allotypes, and IgG1, IgG2 and IgG3, respectively. Additionally, we describe selective associations with IgG4 at 16p11.2 (ITGAX) and 17q21.1 (IKZF3, ZPBP2, GSDMB, ORMDL3). Interestingly, the latter coincides with a highly pleiotropic signal where the allele associated with lower IgG4 levels protects against childhood asthma but predisposes to inflammatory bowel disease. Our results provide insight into the regulation of antibody-mediated immunity that can potentially be useful in the development of antibody based therapeutics.
Uterine carcinosarcoma (UCS) is a rare and highly aggressive gynecological malignancy characterized by poor prognosis. Due to its rarity, UCS remains relatively unexplored, and specific treatment guidelines are scarce. Despite standard treatments, including surgery, adjuvant chemotherapy, and radiotherapy, UCS has a high recurrence rate and poor overall prognosis. The aggressive nature of UCS is attributed to the metaplastic transformation of carcinomatous elements into sarcoma. This "biphasic" neoplasm features a mixture of epithelial and mesenchymal/tumor components, which partially share molecular signatures and exhibit a typical epithelial-to-mesenchymal transition (EMT) gene expression profile. Recent scientific advancements have highlighted the pivotal role of EMT in UCS progression and mortality. This review covers the epidemiology of UCS, theories regarding its origin, and the current state of clinical trials with more emphasis on the role of EMT drivers in UCS progression and scope of targeting these molecules. By shedding light on the molecular mechanisms supporting UCS, particularly emphasizing the importance of EMT, we aim to provide a more comprehensive understanding of the disease to support the development of more effective therapeutic strategies.
1,191,180. Pharmaceutical composition. LABORATOIRES LAROCHE NAVARRON. 25 Sept., 1967 [16 Nov., 1966], No. 43505/67. Heading A5B. A pharmaceutical composition for the treatment of rheumatic osteoarticular conditions and of collager diseases comprises as active principle an admixture of acetylsalicylic acid with the unsaponifiable matter of at least one vegetable oil, e.g. maize, palm, rapeseed, soybean and/or avocado oils. The acetylsalicyclic acid may comprise the major part by weight of the admixture. The unsaponifiable matter of maize oil consists of a mixture of non-hormonal cyclopentanophenanthrenic derivatives such as α, # and γsitosterols and stigmasterol. The compositions may be administered orally or rectally in the form of coated tablets or suppositories respectively containing conventional vehicles and excipients.
<P>PROBLEM TO BE SOLVED: To provide a material for manufacturing an intraluminal stent, and a related method, in which opportunities for designing devices for specific purposes by engineering techniques can be provided to device designers.  <P>SOLUTION: Biocompatible material is usable for designing a variety of implantable medical devices including the intraluminal stent. Using a polymer material, any of the devices including the stent can be produced. The stent may by a balloon-extended type or a self-extended type. By selectively and mechanically deforming the polymer, polymer chains can be oriented to provide different desired kinds of performance characteristics.  <P>COPYRIGHT: (C)2008,JPO&INPIT
This minimal-risk comparison (non-inferiority) study aims to investigate the advantages of Nanodiamond and Amoxicillin modified gutta percha (NDGX) as a root canal filler material for non-surgical root canal therapy. In comparison with the current standard of care, gutta percha (GP), NDGX benefits the patient because NDGX is stronger, may better prevent bacterial reinfection, and potentially reduces complications of non-surgical root canal therapy (RCT) such as tooth fracture, thereby improving overall treatment prognosis. In this study, patients with non-molar teeth needing root canals will be recruited and randomized into two RCT filler material patient groups, with 27 patients with roots filled with the control (GP), and 27 patients with roots filled with NDGX. All patients will be receiving standard of care, and their involvement in our study will only deviate from standard of care in the informed consent process, initial randomization of the root canal filler material, and clinical data collection for research record (already collected in standard of care) from their visits. All patients in the control arm of the study will undergo root canal therapy in which the root canals will be filled with GP. All patients in the NDGX arm of the study will undergo root canal therapy with canals filled with GP in the apical (lower third) end and NDGX in the middle and top thirds of the root canal. In accordance with the standard of care, patients will ideally commit to a total of five visits over a two year period in line with the current standard of care: one pre-treatment consultation appointment, a root canal therapy appointment, a 6 month follow-up appointment, a 1 year follow-up appointment, and a 2 year follow-up appointment. Following standard of care protocol, additional follow-up appointments prior to the 6 month, 1 year, and 2 year follow-up appointments may be required in the event of infection, persistent pain of the root canal following the treatment, and/or at clinician's discretion. Comparison between the control (GP) and NDGX arms of the study will be based upon patient data collected, which will be used to determine clinical "success" derived from reduction and/or absence of a periapical radiolucency and verified with objective and subjective clinical findings such as patient symptoms. Patient data will be categorized by age, weight, gender, and use of other drugs, which may alter the pain assessment and pilot study success indicators.
In general, lower dosages are recommended for these patients. Five mg 3 times a day may be given initially, and increased gradually if necessary. In elderly patients, the cardiovascular system must be monitored closely if the daily dose exceeds 20 mg.

When satisfactory improvement has been reached, dosage should be reduced to the smallest amount that will maintain relief of symptoms.

Minor adverse reactions require reduction in dosage. Major adverse reactions or evidence of hypersensitivity require prompt discontinuation of the drug.

The safety and effectiveness of protriptyline in pediatric patients have not been established.
<P>PROBLEM TO BE SOLVED: To obtain a new Japanese and Chinese medicine which not only mitigates tissue-atrophic pain but also improves leg motor function lesion and leg muscle attenuation by a mitigation action.  <P>SOLUTION: The leg motor function-improving medicine contains Psoralea corylifolia L., Myristica fragrans Houttuyn, and Saussureae lappa Clarke as active ingredients. The ingredients are processed into a powder or a pill together with a binder such as rice paste, except decoction. The Psoralea corylifolia L., the Myristica fragrans Houttuyn, and the Saussureae lappa Clarke are preferably mixed in amounts of 50 pts.wt., 50 pts.wt. and 2.5 to 5 pts.wt., respectively. The leg motor function-improving medicine is administered at a dose of 2 to 8 g twice or three times a day. It is preferable that the Psoralea corylifolia L. is roasted with Sake (rice wine).  <P>COPYRIGHT: (C)2006,JPO&NCIPI